Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Donald Harvey

Showing results (31-40 of 144) with videos related to

Pageof 15
Sort By:
Pharmacotherapy|December 22, 2019
New and Worsening Long-term Immune-Related Adverse Events with PD-1/PD-L1 Pathway Agents in Patients with CancerKevin H Hall, Yuan Liu, Chen Jiang, et al.
JAMA Oncology|April 21, 2022
Enabling the Sharing of Single-Dose Vials Through Risk Mitigation to Decrease Financial ToxicityDaniel A Goldstein, R Donald Harvey, Kelvin K W Chan
Pharmacotherapy|May 1, 2016
Impact of Isotope Dilution Mass Spectrometry (IDMS) Standardization on Carboplatin Dose and Adverse EventsJustin Lawson, Jeffrey M Switchenko, Trevor McKibbin, et al.
The New England Journal of Medicine|May 24, 2018
Rationale, Opportunities, and Reality of Biosimilar MedicationsGary H Lyman, Robin Zon, R Donald Harvey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2026
From Biology to Bedside: Challenges and Strategies in Developing Combination Cancer Therapies in Early-Phase TrialsNiamh Coleman, R Donald Harvey, David S Hong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2018
Reply to S.D. LucioGary H Lyman, Robin Zon, R Donald Harvey, et al.
Journal of Pharmacy Practice|November 8, 2019
The Role of Pharmacists in Managing Adverse Events Related to Immune Checkpoint Inhibitor TherapyPatrick Medina, Kate D Jeffers, Van A Trinh, et al.
Cancer|March 29, 2019
Reply to African American patients may or may not have poorer response rates after monoclonal antibody treatment: Overreliance on P values in underpowered studiesR Donald Harvey, Chao Zhang, Sagar Lonial, et al.
The Annals of Pharmacotherapy|December 29, 2021
Daratumumab for the Treatment of Multiple Myeloma: A Review of Clinical Applicability and Operational ConsiderationsJustin R Arnall, Kathryn T Maples, R Donald Harvey, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 29, 2010
Evaluation of factor VIII pharmacokinetics and anti-factor VIII antibodies in four boys with haemophilia A and a poor clinical response to factor VIIIC L Kempton, S L Meeks, R Donald Harvey, et al.
Pageof 15

Showing results (31-40 of 144) with videos related to

Sort By:
Pageof 15
Pharmacotherapy|December 22, 2019
New and Worsening Long-term Immune-Related Adverse Events with PD-1/PD-L1 Pathway Agents in Patients with CancerKevin H Hall, Yuan Liu, Chen Jiang, et al.
JAMA Oncology|April 21, 2022
Enabling the Sharing of Single-Dose Vials Through Risk Mitigation to Decrease Financial ToxicityDaniel A Goldstein, R Donald Harvey, Kelvin K W Chan
Pharmacotherapy|May 1, 2016
Impact of Isotope Dilution Mass Spectrometry (IDMS) Standardization on Carboplatin Dose and Adverse EventsJustin Lawson, Jeffrey M Switchenko, Trevor McKibbin, et al.
The New England Journal of Medicine|May 24, 2018
Rationale, Opportunities, and Reality of Biosimilar MedicationsGary H Lyman, Robin Zon, R Donald Harvey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2026
From Biology to Bedside: Challenges and Strategies in Developing Combination Cancer Therapies in Early-Phase TrialsNiamh Coleman, R Donald Harvey, David S Hong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2018
Reply to S.D. LucioGary H Lyman, Robin Zon, R Donald Harvey, et al.
Journal of Pharmacy Practice|November 8, 2019
The Role of Pharmacists in Managing Adverse Events Related to Immune Checkpoint Inhibitor TherapyPatrick Medina, Kate D Jeffers, Van A Trinh, et al.
Cancer|March 29, 2019
Reply to African American patients may or may not have poorer response rates after monoclonal antibody treatment: Overreliance on P values in underpowered studiesR Donald Harvey, Chao Zhang, Sagar Lonial, et al.
The Annals of Pharmacotherapy|December 29, 2021
Daratumumab for the Treatment of Multiple Myeloma: A Review of Clinical Applicability and Operational ConsiderationsJustin R Arnall, Kathryn T Maples, R Donald Harvey, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 29, 2010
Evaluation of factor VIII pharmacokinetics and anti-factor VIII antibodies in four boys with haemophilia A and a poor clinical response to factor VIIIC L Kempton, S L Meeks, R Donald Harvey, et al.
Pageof 15